[United States Statutes at Large, Volume 131, 115th Congress, 1st Session]
[From the U.S. Government Publishing Office, www.gpo.gov]


Public Law 115-80
115th Congress

An Act


 
To establish a National Clinical Care Commission. <>

Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled, <>
SECTION 1. SHORT TITLE.

This Act may be cited as the ``National Clinical Care Commission
Act''.
SEC. 2. <>  NATIONAL
CLINICAL CARE COMMISSION.

(a) Establishment.--There is hereby established, within the
Department of Health and Human Services, a National Clinical Care
Commission (in this section referred to as the ``Commission'') to
evaluate and make recommendations regarding improvements to the
coordination and leveraging of programs within the Department and other
Federal agencies related to awareness and clinical care for at least
one, but not more than two, complex metabolic or autoimmune diseases
resulting from issues related to insulin that represent a significant
disease burden in the United States, which may include complications due
to such diseases.
(b) Membership.--
(1) In general.--The Commission shall be composed of the
following voting members:
(A) The heads of the following Federal agencies and
departments, or their designees:
(i) The Centers for Medicare & Medicaid
Services.
(ii) The Agency for Healthcare Research and
Quality.
(iii) The Centers for Disease Control and
Prevention.
(iv) The Indian Health Service.
(v) The Department of Veterans Affairs.
(vi) The National Institutes of Health.
(vii) The Food and Drug Administration.
(viii) The Health Resources and Services
Administration.
(ix) The Department of Defense.
(x) The Department of Agriculture.
(xi) The Office of Minority Health.
(B) Twelve additional voting members appointed under
paragraph (2).
(2) Additional members.--The Commission shall include
additional voting members, as may be appointed by the Secretary,
with expertise in the prevention, care, and epidemiology of any
of the diseases and complications described in subsection

[[Page 1262]]

(a), including one or more such members from each of the
following categories:
(A) Physician specialties, including clinical
endocrinologists, that play a role in the prevention or
treatment of diseases and complications described in
subsection (a).
(B) Primary care physicians.
(C) Non-physician health care professionals.
(D) Patient advocates.
(E) National experts, including public health
experts, in the duties listed under subsection (c).
(F) Health care providers furnishing services to a
patient population that consists of a high percentage
(as specified by the Secretary) of individuals who are
enrolled in a State plan under title XIX of the Social
Security Act or who are not covered under a health plan
or health insurance coverage.
(3) Chairperson.--The members of the Commission shall select
a chairperson from the members appointed under paragraph (2).
(4) Meetings.--The Commission shall meet at least twice, and
not more than four times, a year.
(5) Vacancies.--A vacancy on the Commission shall be filled
in the same manner as the original appointments.

(c) Duties.--The Commission shall evaluate and make recommendations,
as appropriate, to the Secretary of Health and Human Services and
Congress regarding--
(1) Federal programs of the Department of Health and Human
Services that focus on preventing and reducing the incidence of
the diseases and complications described in subsection (a);
(2) current activities and gaps in Federal efforts to
support clinicians in providing integrated, high-quality care to
individuals with the diseases and complications described in
subsection (a);
(3) the improvement in, and improved coordination of,
Federal education and awareness activities related to the
prevention and treatment of the diseases and complications
described in subsection (a), which may include the utilization
of new and existing technologies;
(4) methods for outreach and dissemination of education and
awareness materials that--
(A) address the diseases and complications described
in subsection (a);
(B) are funded by the Federal Government; and
(C) are intended for health care professionals and
the public; and
(5) whether there are opportunities for consolidation of
inappropriately overlapping or duplicative Federal programs
related to the diseases and complications described in
subsection (a).

(d) <>  Operating Plan.--Not later than 90 days
after its first meeting, the Commission shall submit to the Secretary of
Health and Human Services and the Congress an operating plan for
carrying out the activities of the Commission as described in subsection
(c). <>  Such operating plan may include--

[[Page 1263]]

(1) a list of specific activities that the Commission plans
to conduct for purposes of carrying out the duties described in
each of the paragraphs in subsection (c);
(2) a plan for completing the activities;
(3) a list of members of the Commission and other
individuals who are not members of the Commission who will need
to be involved to conduct such activities;
(4) an explanation of Federal agency involvement and
coordination needed to conduct such activities;
(5) <>  a budget for conducting such
activities; and
(6) other information that the Commission deems appropriate.

(e) Final Report.--By not later than 3 years after the date of the
Commission's first meeting, the Commission shall submit to the Secretary
of Health and Human Services and the Congress a final report containing
all of the findings and recommendations required by this section.
(f) Sunset.--The Commission shall terminate 60 days after submitting
its final report, but not later than the end of fiscal year 2021.

Approved November 2, 2017.

LEGISLATIVE HISTORY--S. 920:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 163 (2017):
Sept. 6, considered and passed Senate.
Oct. 11, considered and passed House.